8月7日，10x Genomics盘后下跌5.26%，报43.0美元/股，成交额447.45万美元。
消息面上，公司于盘后发布第二季度财报，虽然每股亏损0.14美元优于市场预期的亏损0.24美元，营收1.51亿美元亦超出预期的1.47亿美元，但营收同比大幅下降12.7%（去年同期为1.729亿美元），且由去年同期每股盈利0.28美元转为亏损，基本面恶化趋势引发市场抛压。公司同时上调全年营收指引至6.1亿至6.3亿美元，高于此前的6.0亿至6.25亿美元区间，略高于分析师预期的6.137亿美元。
10x Genomics是一家生命科学技术公司，专注于开发创新产品和解决方案以探究、理解并掌控生物学，其集成研究解决方案包括用于分析生物系统的仪器、耗材和软件。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.